Boehringer Ingelheim and Lilly Diabetes Alliance to Present Data from 35 Studies at the American Diabetes Association’s^® 75th Scientific Sessions

Ingelheim, Germany and Indianapolis, US, May 27, 2015 – The presentation of 35 abstracts will demonstrate the breadth and depth of the Boehringer Ingelheim and Eli Lilly and Company Diabetes alliance portfolio June 5-9 at the American Diabetes Association’s (ADA) 75th Scientific Sessions in Boston.

“With growing numbers of people being diagnosed with diabetes, there is tremendous need for ongoing clinical research to ensure treatment options and approaches are available to meet patients’ diverse needs,” said Professor Hans-J. Woerle, Vice President, Head of Medicine, Therapeutic Area Metabolism, Boehringer Ingelheim. “As part of our commitment to the diabetes community, the BI-Lilly Diabetes alliance will present an array of product, disease state and patient-physician survey data that help address the needs of adults with diabetes.”

Highlighted presentations and posters include:

Empagliflozin/Metformin Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session

• Initial Combinations of Empagliflozin and Metformin in Patients with Type 2 Diabetes
  (Presenting Author: Hadjadj, S.) [119-LB]³

Empagliflozin plus immediate-release metformin hydrochloride is being studied for the treatment of adults with type 2 diabetes (T2D). Data on this combination will be discussed in a late-breaker poster presentation.

IntroDia Survey Patient Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session
 

• Physician-Patient Communication At Prescription of an Additional Oral Agent for Type 2 Diabetes (T2D): Link Between Key Conversation Elements, Physician Empathy and Patient Outcomes - Insights From the Global IntroDia^™ Study (Presenting Author: Capehorn, M.) [63-LB]⁴

IntroDia is the largest global patient and physician survey ever conducted that focuses on early conversations about T2D – providing insights into how physicians and patients interact at important moments of the diabetes treatment journey. New results from the survey will be presented as a late-breaker poster presentation.

Trajenta (linagliptin) Data
Sunday, June 7, 2015: 12 p.m. – 2 p.m. EDT – General Poster Session

• Safety and Efficacy of Linagliptin in Patients with Type 2 Diabetes (T2D) and Coronary Artery Disease (CAD): Analysis Of Pooled Incident Investigator Reported Events From Phase 3 Clinical Trials (Presenting Author: Leiter, L.) [1246-P]²

Linagliptin (5mg, once-daily tablet), marketed as Trajenta (linagliptin) in Europe and Tradjenta (linagliptin) in the U.S., is a DPP-4 inhibitor, which works by increasing hormone levels that stimulate the pancreas to produce more insulin and the liver to produce less glucose¹. Data will be presented as a poster presentation.

A complete list of alliance abstracts to be presented or published at the ADA’s Scientific Sessions can be found here.

Boehringer Ingelheim and Eli Lilly and Company
In January 2011, Boehringer Ingelheim and Eli Lilly and Company announced an alliance in diabetes that centres on compounds representing several of the largest diabetes treatment classes. The alliance leverages the strengths of two of the world’s leading pharmaceutical companies. By joining forces, the companies demonstrate commitment in the care of patients with diabetes and stand together to focus on patient needs. Depending on geographies, the companies either co-promote or separately promote the respective molecules each contributed to the alliance.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 146 affiliates and a total of more than 47,700 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2014, Boehringer Ingelheim achieved net sales of about 13.3 billion euros. R&D expenditure corresponds to 19.9 percent of its net sales.

For more information please visit www.boehringer-ingelheim.com

About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a broad and growing product portfolio and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.

This press release contains forward looking statements about TRAJENTA and empagliflozin/metformin for the treatment of type 2 diabetes along with diet and exercise. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date, that empagliflozin/ metformin  will be approved or be commercially successful, or TRAJENTA will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements.

Intended audiences
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.